Irhythm Technologies [IRTC] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Irhythm Technologies Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Irhythm Technologies Inc. wins in 2 metrics, Abbott Laboratories wins in 17 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Irhythm Technologies Inc. Abbott Laboratories Better
P/E Ratio (TTM) -87.47 25.97 Abbott Laboratories
Price-to-Book Ratio 25.14 3.09 Abbott Laboratories
Debt-to-Equity Ratio 478.69 26.79 Abbott Laboratories
PEG Ratio 0.17 -1.41 Irhythm Technologies Inc.
EV/EBITDA -130.50 13.74 Abbott Laboratories
Profit Margin (TTM) -5.96% 13.90% Abbott Laboratories
Operating Margin (TTM) 4.20% 16.50% Abbott Laboratories
EBITDA Margin (TTM) 4.20% 16.50% Abbott Laboratories
Return on Equity -36.57% 12.36% Abbott Laboratories
Return on Assets (TTM) -2.36% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $34.52M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -18.93% -35.92% Irhythm Technologies Inc.
Price-to-Sales Ratio (TTM) 5.23 3.57 Abbott Laboratories
Enterprise Value $3.99B $166.96B Abbott Laboratories
EV/Revenue Ratio 5.34 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 70.88% N/A N/A
Revenue per Share (TTM) $23 $26 Abbott Laboratories
Earnings per Share (Diluted) $-1.39 $3.57 Abbott Laboratories
Beta (Stock Volatility) 1.18 0.78 Abbott Laboratories
Short % of Float 10.20% 1.53% Abbott Laboratories

Irhythm Technologies Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

IRTC
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Irhythm Technologies Inc.2.67%-6.13%-12.27%-16.92%-42.88%-40.33%
Abbott Laboratories4.36%1.53%-0.63%-23.43%-30.57%-29.95%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Irhythm Technologies Inc.-18.93%7.80%83.44%341.64%341.64%341.64%
Abbott Laboratories-35.92%-17.85%-21.68%118.48%249.25%313.73%

Performance & Financial Health Analysis: Irhythm Technologies Inc. vs Abbott Laboratories

MetricIRTCABT
Market Information
Market Cap i$3.99B$160.70B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i379,43313,495,583
90 Day Avg. Volume i483,82412,934,461
Last Close$107.35$90.78
52 Week Range$101.75 - $212.00$81.97 - $139.06
% from 52W High-49.36%-34.72%
All-Time High$286.19 (Jan 25, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-62.49%-36.34%
Growth Metrics
Quarterly Revenue Growth0.27%0.08%
Quarterly Earnings Growth0.27%-0.19%
Financial Health
Profit Margin (TTM) i-0.06%0.14%
Operating Margin (TTM) i0.04%0.17%
Return on Equity (TTM) i-0.37%0.12%
Debt to Equity (MRQ) i478.6926.79
Cash & Liquidity
Book Value per Share (MRQ)$4.73$30.02
Cash per Share (MRQ)$18.06$5.14
Operating Cash Flow (TTM) i$80.86M$10.80B
Levered Free Cash Flow (TTM) i$71.67M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Irhythm Technologies Inc. vs Abbott Laboratories

MetricIRTC (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-87.4725.97
Forward P/E i142.1415.29
PEG Ratio i0.17-1.41
Price to Sales (TTM) i5.233.57
Price to Book (MRQ) i25.143.09
Market Capitalization
Market Capitalization i$3.99B$160.70B
Enterprise Value i$3.99B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i5.343.70
Enterprise to EBITDA i-130.5013.74
Risk & Other Metrics
Beta i1.180.78
Book Value per Share (MRQ) i$4.73$30.02

Financial Statements Comparison: Irhythm Technologies Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricIRTC (2025)ABT (2025)
Revenue/Sales i747.14M44.33B
Cost of Goods Sold i219.89M19.32B
COGS % of Revenue i29.4%43.6%
Gross Profit i527.25M25.01B
Gross Margin i70.6%56.4%
Research & Development i84.61M2.94B
Operating Income (EBIT) i-49.91M8.05B
Operating Margin i-6.7%18.2%
EBITDA i3.53M12.03B
EBITDA Margin i0.5%27.1%
Pre-Tax Income i-43.60M8.47B
Pre-Tax Income % of Revenue i-5.8%19.1%
Income Tax i953,0001.94B
Income Tax % of Revenue i0.1%4.4%
Net Income (Profit) i-44.55M6.52B
Profit Margin i-6.0%14.7%

Balance Sheet & Liquidity Metrics

MetricIRTC (2025)ABT (2025)
Cash & Equivalents i236.01M8.52B
Total Current Assets i702.77M26.00B
Total Current Assets % of Revenue i94.1%58.6%
Total Current Liabilities i151.89M16.50B
Total Current Liabilities % of Revenue i20.3%37.2%
Long-Term Debt i714.50M10.83B
Long-Term Debt % of Revenue i95.6%24.4%
Total Shareholders Equity i152.75M52.77B
Retained Earnings i-803.45M49.78B
Retained Earnings % of Revenue i-107.5%112.3%
Property, Plant & Equipment i59.45M17.57B

Cash Flow Statement Comparison

MetricIRTC (2025)ABT (2025)
Operating Cash Flow i-37.09M10.80B
Operating Cash Flow % of Revenue i-5.0%24.4%
Capital Expenditures i-46.34M-2.17B
Free Cash Flow i34.52M7.40B
FCF Margin i4.6%16.7%
Debt Repayment i0-1.50B
Common Stock Repurchase i0-893.00M

Short Interest & Institutional Ownership Analysis

MetricIRTCABT
Shares Short i2.94M23.83M
Short Ratio i4.571.93
Short % of Float i10.20%1.53%
Shares Outstanding i32.30M1.74B
Float Shares i30.29M1.73B
% Held by Insiders i1.23%0.54%
% Held by Institutions i112.51%82.23%
% Held by Public i-13.74%17.23%

Dividend Analysis & Yield Comparison: Irhythm Technologies Inc. vs Abbott Laboratories

MetricIRTCABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026